Laguna Biotherapeutics Reports the US FDA IND Clearance for LGNA-100 to Treat High-Risk Pediatric Leukemias

Shots: The US FDA has granted IND clearance to LGNA-100, Laguna Biotherapeutics’ lead clinical candidate from the QUAIL platform, to initiate the P-I trial The P-I single ascending dose study will assess safety, tolerability, & mechanism of LGNA-100 via IV infusion in pediatric & young adults with high-risk acute leukemias & MDS post αβ-depleted HSCT…

ByRidhi RastogiApril 30, 2026

VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies

Shots: VERAXA to reverse merge with Voyager, where the combined entity- "VERAXA Biotech” will be listed on Nasdaq under VERX ticker; closing expected in Q4’25 As per the deal, VERAXA will have access to ~$253M cash from Voyager’s trust at closing & contribute ~$1.3B in equity for ~130M shares, with all shareholders rolling over 100%…

ByRidhi RastogiApril 23, 2025

Clinical Trial to Study Effectiveness of Cancer Treatment Administered 2024

There are tons of clinical trials taking place at this moment. It’s a nasty disease and it’s important to figure out different ways to diagnose it, treat it, and, if possible, prevent it. 2024 brings on innovations in this field. It can probably shed light on how cancer can become more treatable and not such…

ByJack TurnerJune 20, 2024

Laguna Biotherapeutics Reports the US FDA IND Clearance for LGNA-100 to Treat High-Risk Pediatric Leukemias

VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies

Clinical Trial to Study Effectiveness of Cancer Treatment Administered 2024

Contact US

FOLLOW US